ライフサイエンスコーパス: oral dose

1 dose) or a high dose (2.5 times the previous oral dose).

2 erences in study design (e.g., injection vs. oral dosing).

3 ribution of reserpine at 2 h post a 20 mg/kg oral dose.

4 uito-killing drug for 10 days after a single oral dose.

5 the retinol-RBP molar ratio triggered by the oral dose.

6 marrow and spleen within 6 hours of a single oral dose.

7 te of protection) within 10 days of a single oral dose.

8 ts and cynomolgus monkeys following a single oral dose.

9 ticles (160 individual components) targeting oral dose.

10 m-infected mice, providing a cure after four oral doses.

11 gh free exposure in mouse following moderate oral doses.

12 ies generally exhibited good efficacy at low oral doses.

13 each cured 3/4 mice with four daily 25 mg/kg oral doses.

14 acitidine exposure increased with escalating oral doses.

15 dose, and two other dimers cure after three oral doses.

16 nflammatory and neuropathic pain models upon oral dosing.

17 xposure in rat pharmacokinetic studies after oral dosing.

18 y improved by administration of TTT-3002 via oral dosing.

19 th vaginal dosing and only 19% of women with oral dosing.

20 for its use is sparse and limited to use of oral dosing.

21 d in vivo bioavailability after either iv or oral dosing.

22 om the androgenic activity on prostate after oral dosing.

23 ta-amyloid peptides in mouse brain following oral dosing.

24 show robust in vivo target engagement after oral dosing.

25 e (Abeta) levels in wild-type rats following oral dosing.

26 compounds with prolonged exposure following oral dosing.

27 d total cholesterol levels in rats following oral dosing.

28 s dose dependent and supported twice per day oral dosing.

29 r activity, and rat liver exposure following oral dosing.

30 active triphosphate species following single oral dosing.

31 vage fluid in allergen-challenged mice after oral dosing.

32 RO4929097 is active following oral dosing.

33 cy was achieved in preclinical species after oral dosing.

34 hown to exhibit bioavailability of 76% after oral dosing.

35 ty in blood levels of TDF that resulted from oral dosing.

36 tumor growth inhibition at 50 mg/kg QD upon oral dosing.

37 achieved good pharmacokinetics in dogs with oral dosing.

38 tagonism in several in vivo models following oral dosing.

39 e demonstrated exposure in animals following oral dosing.

40 idence for tumor growth inhibition following oral dosing.

41 amyloid-beta (Abeta) in the CNS after acute oral dosing.

42 potency and good brain penetration following oral dosing.

43 Oral dosing (0.03 mg/kg) of 16 in rats 1 h prior to LPS

44 onstrated anticoagulant effects at 2 h after oral dosing (100 mg.kg(-1)), with a significant 43% prol

45 ction of brain Abeta was 40-50%, 1.5 h after oral dosing (100 mumol/kg).

46 e-blind treatment with tolvaptan at a single oral dose (15, 30, or 60 mg) or placebo.

47 Single doses (0.25 to 100 mg) and repeated oral doses (2.5 to 20 mg for 10 days) of BIA 10-2474 had

48 d 15 healthy women (controls) given a single oral dose (20 mg or 200 mg) of the CRF-R1 antagonist or

49 vax malaria received artefenomel in a single oral dose (200 mg, 400 mg, 800 mg, or 1200 mg).

50 lthy volunteers received 2 escalating single oral doses (35-1500 mg) of PNU-100480 or placebo.

51 was also curative in this model in a single oral dose (80 mg/kg).

52 Five days after oral dosing, a zinc tracer was infused intravenously.

53 man pharmacokinetics suitable for once a day oral dosing, achieved its pharmacodynamic target for PAR

54 s, mice were given 5 transdermal doses and 5 oral doses administered alternatively, beginning with tr

55 on of their antimalarial efficacy via single oral dose administration in two 60-day survival studies

56 d circulating reticulocytes following single oral dose administration, while 4-week q.d. po administr

57 Relationships between oral dose and biomarker concentrations were assessed usi

58 ixaban differ from warfarin with their fixed oral dose and no requirement for routine monitoring.

59 .4% after administration of 100 mg/kg single oral dose and prolonged mice survival by an average of 1

60 stently positive linear relationship between oral dose and urinary concentration was observed (R2 > 0

61 ty compared with clopidogrel before the next oral dose and, although platelet reactivity was lower wi

62 With 300-400 mg twice-daily oral doses and 200-300 mg twice-daily intravenous doses,

63 t exposure protocols were used: single daily oral doses and continuous exposure via subdermal implant

64 22 exhibited good pharmacokinetics following oral dosing and showed potent inhibition of VEGF-induced

65 vity vs S1P3 receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for p

66 Abeta levels in rat CSF and brain following oral dosing, and compound 37 exhibited an improved cardi

67 GLPG0634 was well exposed in rodents upon oral dosing, and exposure levels correlated with repress

68 strated in vivo tumor growth inhibition upon oral dosing, and was selected for preclinical evaluation

69 significantly CSF Abeta40 and 42 in rats at oral doses as low as 1 mg/kg.

70 iting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) stu

71 ioxane dimers cure malaria-infected mice via oral dosing at 3 x 30 mg/kg.

72 antly reduced proteoglycan release following oral dosing at 30 mg/kg (75% inhibition, p < 0.05) and a

73 drogenic activity on ventral prostate, after oral dosing at 30 mg/kg.

74 i infected mice in 3/6 derivatives following oral dosing at 4 x 30 mg/kg, with microsomal metabolic s

75 An oral dose, at 200mg/kg/day, resulted in significant decl

76 prolonged inhibition of Kit was achieved at oral doses between 10 and 50 mg/kg and this dose range w

77 study, compound 9t was brain-penetrant after oral dosing, but exposure was limited by high plasma cle

78 t radioprotection in mice at single nontoxic oral dose by a dose-reduction factor of 1.28.

79 Following oral dosing, compounds 12 and 42 gave a statistical redu

80 rd-trimester fetuses exposed to single daily oral doses during the time of follicle formation reveale

81 imus was administered alone as a single 2-mg oral dose, followed by a minimum 14-day washout period,

82 ne was administered alone as a single 100-mg oral dose, followed by a minimum 8-day washout period, a

83 ous hydrocortisone equivalent to presurgical oral dosing, followed by taper).

84 ablished T. cruzi infection after once daily oral dosing for 20 days at 20 mg/kg 6 and 10 mg/kg (S)-7

85 and reverse toxicokinetics, to obtain human oral dose hazard values that are similar to published ma

86 as protect at-risk populations with a single oral dose, highlighting the strength of diversity-orient

87 f B16 melanoma tumors in mice at a tolerated oral dose in a T cell-dependent manner but had little ef

88 ed with high potency, led to a predicted low oral dose in humans.

89 ntrolled, randomized trial evaluating single oral doses in healthy adult males.

90 After oral dosing in a rat atrophied levator ani muscle model,

91 d 34 showed improved glucose tolerance after oral dosing in an oral glucose tolerance test.

92 ntify a nodulisporamide suitable for monthly oral dosing in dogs, a library of 335 nodulisporamides w

93 issolution rate-limited absorption following oral dosing in humans.

94 Chronic oral dosing in male rhesus macaques was well tolerated,

95 tional downstream effector (p70S6) following oral dosing in mice.

96 hed that 13-d had properties compatible with oral dosing in mouse models of disease (Fpo 49%).

97 rtually undetectable levels after once daily oral dosing in mouse models of T. cruzi infection.

98 essfully reducing brain Htt levels following oral dosing in rats.

99 ions displayed sustained plasma levels after oral dosing in rodents leading to efficacy in the P. fal

100 A high drug exposure NOEL on oral dosing in the rat suggested that a high therapeutic

101 The pharmacokinetics of 6 following a single oral dose indicated that the prodrug was rapidly absorbe

102 t target engagement in mouse liver following oral dosing, leading to improved lipid metabolism and in

103 dels of type 2 diabetes revealed that single oral doses lowered hyperglycemia within 60 min, enhanced

104 ellent solubility at low pH, suggesting that oral dosing may be possible.

105 Comparison with the oral doses obtained when flies were fed an IMI-sucrose m

106 A man was given an oral dose of 0.001821 micromol [5-14CH3]RRR-alpha-tocoph

107 the second night, 1 group received a single oral dose of 0.25mg pramipexole, whereas a second group

108 iod, all of the subjects received a one-time oral dose of 0.5 mg trans-resveratrol/kg body weight in

109 le, whereas a second group received a single oral dose of 0.5mg clonazepam, and the remaining patient

110 nd demonstrated 50% receptor occupancy at an oral dose of 0.8 mg/kg in rats and an intravenous dose o

111 ompound 18 proved to be useful, which at low oral dose of 1 (mg/kg)/day body weight increased bone ma

112 olesteryl ester (CE) transfer activity at an oral dose of 1 mg/kg in human CETP/apoB-100 dual transge

113 old greater than that produced by a 30 mg/kg oral dose of 1.

114 Single oral dose of 10 mg of dexamethasone (n = 293) or identic

115 plasma viral loads were administered a daily oral dose of 10 mg/kg for 35 days.

116 male C57BL/6 mice were treated with a single oral dose of 10 mug/kg TCDD.

117 In mice treated with a single oral dose of 10 mumol SFN, there was significant inhibit

118 In healthy adults (n=4), 2 hr after a single oral dose of 10-mg TAC, the p38 MAPK activation was inhi

119 We then administered either cortisol (single oral dose of 100 mg hydrocortisone, N = 34) or testoster

120 randomly assigned to receive either a bolus oral dose of 100,000 IU cholecalciferol followed by 4000

121 (30 subjects) was supplemented with a single oral dose of 100,000 IU cholecalciferol.

122 ely cured malaria-infected mice via a single oral dose of 144 mg/kg.

123 mpare the antisecretory response to a single oral dose of 20 mg rabeprazole, 20 mg omeprazole and pla

124 ndomly assigned to receive either an initial oral dose of 200 000 IU (5.0 mg) colecalciferol (vitamin

125 All children received one oral dose of 30 mg/kg azithromycin.

126 Ten new trioxane dimers at only a single oral dose of 30 mg/kg prolong mouse average survival to

127 asmodium berghei-infected mice with a single oral dose of 30 mg/kg.

128 were screened for their response to a single oral dose of 325-mg immediate release or enteric coated

129 Each participant consumed a single oral dose of 35 mg (13)C-EPA and its metabolism was foll

130 omparison of DPS and plasma was made (single oral dose of 37.5 mg of paroxetine).

131 ystemic exposure of 1 produced by a 10 mg/kg oral dose of 3a was 2.5-fold greater than that produced

132 ce, compound 4 was completely curative at an oral dose of 4 x 10 mg/kg.

133 ere performed, each with the use of a single oral dose of 40 mg (13)C-DHA.

134 Following an oral dose of 40 mg/kg/day for 30 days, quinacrine concen

135 One group was given an oral dose of 45 mg zinc/d as a gluconate for 6 mo.

136 rticipants in both groups in a daily divided oral dose of 45 mg/m(2) until remission, or until day 60

137 An oral dose of 5 mg/kg QD is well tolerated and results in

138 ir in the RPV/rabbit model and found that an oral dose of 5 mg/kg twice a day for 5 days beginning 1

139 lation (TMS) to test the effects of a single oral dose of 50 and 100 mg of S44819 on electromyographi

140 8 d, the same participants consumed a single oral dose of 50 mg (13)C-AA and its metabolism was follo

141 ation and distribution of clozapine after an oral dose of 50 mg/kg by: i) measuring the abundance of

142 essfully applied to a clinical study (single oral dose of 500 mg or 1 g acetaminophen).

143 n metastatic melanoma patients treated at an oral dose of 960 mg twice daily.

144 A single oral dose of [(14)C]metformin was administered to C57BL/

145 A prophylactic oral dose of a FimH small-molecular-weight antagonist (Z

146 However, 1 oral dose of a small-molecular-weight compound that inhi

147 A healthy man was given an oral dose of all-trans [10,10',11,11'-(14)C]-beta-carote

148 eriment 1, we tested the effects of a single oral dose of alprazolam (a classical benzodiazepine acti

149 troprusside [90 to 900 ng/min]), or a single oral dose of aspirin (600 mg) or matched placebo.

150 and PCR conversion to HD negative, a single oral dose of azithromycin is efficacious for the treatme

151 302 of 16,092 residents (82.7%) received one oral dose of azithromycin.

152 gned to also receive placebo (n=269), single oral dose of casopitant mesylate (150 mg oral, n=271), o

153 f 25-hydroxyvitamin D (calcidiol) to a large oral dose of cholecalciferol.

154 The effects of a single oral dose of cis-N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-

155 A single oral dose of compound 11a resulted in a significant redu

156 An oral dose of CsA was administered to 24 healthy voluntee

157 ubsequent coadministration of a single 10-mg oral dose of cyclosporine with either a single dose of t

158 ntanil PET before and 3 hours after a single oral dose of d-amphetamine (either a "high" dose, .5 mg/

159 ) with [(18)F]fallypride before and after an oral dose of d-amphetamine.

160 Humans treated with a single oral dose of DADMe-ImmH in phase 1 clinical trials exhib

161 A single oral dose of disulfiram inhibited about 70% of the deflu

162 ry duct-ligated (BDL) rats received a single oral dose of droxidopa (25-50 mg/kg) or vehicle and hemo

163 A 600-mg oral dose of efavirenz was subsequently administered, an

164 th fMRI twice, one month apart, following an oral dose of either delta-9-THC (10 mg) or placebo, whil

165 diet) and treated on postnatal day 4 with an oral dose of either VA (6 mug retinyl palmitate/g body w

166 This trial shows that a single oral dose of encapsulated glutamine can promote increase

167 Following a single oral dose of gefitinib (50 or 150 mg/kg), tumors were pr

168 ants were randomized 1:1:1:1 to a once-daily oral dose of GSK1278863 (0.5 mg, 2 mg, or 5 mg) or contr

169 nal receptor binding (VT) following a single oral dose of GSK598809 (60 mg) were consistent with thos

170 assessed the activity and tolerability of an oral dose of imatinib mesylate 400 mg twice daily in pat

171 A single oral dose of irinotecan was given on day 9 of course 2 t

172 tecan and on the bioavailability of a single oral dose of irinotecan.

173 A time course simulation following an oral dose of iron was compared to a clinical time course

174 Animals were given a single oral dose of KBrO(3) (100mg/kg body weight) and sacrific

175 The renal effects of single oral dose of KBrO(3) appeared to be reversible; maximum

176 ed the efficacy and safety of a single daily oral dose of moxifloxacin with oral combination therapy

177 ting the pharmacodynamic effects of a single oral dose of NDI-010976 on hepatic DNL in overweight and

178 -day period after administration of a 200-mg oral dose of nevirapine to nonpregnant, HIV-negative Afr

179 ) can rise as much as 2.7-fold with a single oral dose of NR in a pilot study of one individual, and

180 ehavioural impact of informing smokers their oral dose of NRT is tailored to analysis of DNA.

181 Informing smokers their oral dose of NRT was tailored to genotype not phenotype

182 At a much lower single oral dose of only 54 mg/kg combined with 13 mg/kg of mef

183 Upon receiving a single oral dose of only 6 mg/kg of the monomeric trioxane 12c

184 Upon one oral dose of only 6.8 mg/kg of monomeric trioxane 4b com

185 time course of 25 h after intake of a single oral dose of phentermine.

186 betic fatty (ZDF) rats 45 min after a single oral dose of pioglitazone (30 mg/kg).

187 four pharmacological conditions: (1) single oral dose of placebo, (2) 4 mg of the selective NE-reupt

188 A single oral dose of propranolol (40 mg) significantly increased

189 Subsequent evaluation revealed that a single oral dose of purified, soluble CFA/I fimbriae protected

190 cacy documented 10 days and 3 months after 1 oral dose of PXVX0200 supports further development as a

191 Remarkably, a single oral dose of SAR405838 is sufficient to achieve complete

192 bolism in humans and mice following a single oral dose of saturated fat.

193 Meanwhile, a single oral dose of shizukaol F reduced gluconeogenesis in C57B

194 fraction, 60 +/- 14%) who received a single oral dose of sildenafil (40 or 80 mg).

195 We tested the hypothesis that a single oral dose of sildenafil (50 mg) would improve exercise c

196 n healthy volunteers in response to a single oral dose of sitagliptin.

197 sign and all participants ingested either an oral dose of synthetic THC (n=41) or placebo (n=37) befo

198 An oral dose of TD or GP of SM was administrated to subject

199 afety, tolerability, and recommended phase 2 oral dose of the CCR2 inhibitor PF-04136309 in combinati

200 o treatment groups who received at least one oral dose of tosedostat.

201 Susceptibility of mice treated with a single oral dose of up to 50 mg/kg WAY-202196 did not differ fr

202 ld, were randomly allocated 1:1 to receive 1 oral dose of vaccine (approximately 5 x 10(8) colony-for

203 1:1) participants to receive either a single oral dose of vaccine or placebo.

204 y assigned (ratio 1:1) to receive either one oral dose of vitamin A (50,000 IU) or placebo immediatel

205 hy volunteers, supplementation with a single oral dose of vitamin D (100,000 IU vitamin D2) increased

206 Oral doses of 0.5 or 2.0 g SRT2104 or matching placebo w

207 Twice-daily oral doses of 100 mg and 150 mg of R788 were significant

208 ties (October 2012-July 2013) compared daily oral doses of 100 mg of pritelivir with 500 mg of valacy

209 the NCI-H526 xenograft model was observed at oral doses of 100 to 200 mg/kg, which was the dose level

210 althy men (age range, 21-50 years) at single oral doses of 100, 140, or 280mg (n = 5 per group).

211 namic studies in APP51/16 transgenic mice at oral doses of 180 mumol/kg demonstrated significant redu

212 At oral doses of 20-50 mg/kg given after establishment of p

213 They received oral doses of 25 mg of dnaJP1 or placebo daily for 6 mon

214 Mice were given oral doses of 2ME2 (75 mg/kg), with radiation fractions

215 t with diet-induced obesity following single oral doses of 3 and 10 mg/kg.

216 Patients were randomized (1:1:1) to receive oral doses of 3 mg of macitentan, 10 mg of macitentan, o

217 3 log viral load reduction in monotherapy at oral doses of 3 mg or greater with once-daily dosing in

218 ents were allocated to receive six 2-monthly oral doses of 3 mg vitamin D3 or placebo over 1 year in

219 gulatory dysfunction and were efficacious at oral doses of 3 mg/kg in reducing the tail skin temperat

220 ificantly superior to placebo or twice-daily oral doses of 50 mg at week 12 (ACR20 achieved in 65% an

221 (LDL-C) and triglycerides (TG) at once daily oral doses of 50 mg or higher given for 2 weeks.

222 Participants received oral doses of abiraterone acetate (1000 mg daily) and pr

223 We administered various oral doses of alectinib (300-900 mg twice a day) during

224 (NZB x NZW)F1 (NZB/NZW) mice received daily oral doses of atorvastatin for 20 weeks.

225 atio to receive either two directly observed oral doses of cholecalciferol (300,000 IU) or matching p

226 cted patients after administration of single oral doses of DCV.

227 ject Monte Carlo experiments to identify the oral doses of linezolid, moxifloxacin, and faropenem tha

228 u(1 + 2) were observed in patients receiving oral doses of MTX, whereas higher concentrations of MTXG

229 ment-resistant major depression received two oral doses of psilocybin (10 mg and 25 mg, 7 days apart)

230 A. ceylanicum were treated with three daily oral doses of purified Cry5B, the benzimidazole anthelmi

231 We randomly assigned 42 patients to receive oral doses of sapropterin (10 mg/kg) and 47 patients to

232 We conducted a phase 2 trial of 2 oral doses of solithromycin (1200 and 1000 mg) for treat

233 The effects on behavior of daily oral doses of sulforaphane (50-150 micromol) for 18 wk,

234 ious treatment status, to receive once-daily oral doses of tenofovir alafenamide 25 mg or tenofovir d

235 lymphopoietin (TSLP) and antigen to repeated oral doses of the same antigen induced acute diarrhea an

236 tected in the brains of animals after single oral doses of these agents.

237 dent study examined the relationship between oral doses of three widely used personal care product in

238 al study NP22657 (BRIM-2), patients received oral doses of vemurafenib (960 mg twice per day).

239 gation and puncture model, in which multiple oral doses of WAY-202196 (50 mg/kg) improved survival (8

240 kg doxorubicin, 0.375 mg/kg vincristine, and oral dosing of 0.15 mg/kg prednisone once a day for 5 da

241 Oral dosing of 2 or 4 yielded a dose-dependent decrease

242 mRNA induction (2.7-fold over vehicle) upon oral dosing of 27 at 300 mg/kg.

243 ood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

244 reductions in lumbar CSF were measured after oral dosing of 30 or 90 mg of LY2811376.

245 Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt

246 Oral dosing of 58 reduced food intake in an acute rat fe

247 Oral dosing of compound 2 to mice resulted in a dose-dep

248 Twice-daily oral dosing of delamanid at 30 mg kg(-1) for 5 days resu

249 Oral dosing of EZM2302 demonstrates dose-dependent in vi

250 Oral dosing of GLPG0634 in a therapeutic set-up in a col

251 pendent inhibition in wild-type mice through oral dosing of JNJ-54271074.

252 Once daily oral dosing of LY2940094 at 40 mg for 8 weeks vs placebo

253 If frequent oral dosing of PPIs provided similar antisecretory effec

254 In addition, after oral dosing of several phosphoramidate derivatives of co

255 In vivo PCSK9 lowering by oral dosing of the candidate prodrug and quantification

256 rease in circulating levels of PTH following oral dosing of the ester prodrug 11 in the dog.

257 Oral dosing of these compounds in diabetic mice induces

258 ransplant model is significantly improved by oral dosing of TTT-3002.

259 A three-drug regimen including a single oral dose or 3-day intravenous plus oral regimen of caso

260 w dose (equivalent to the patient's previous oral dose) or a high dose (2.5 times the previous oral d

261 s.c. doses (s.c. F1-V mice) or unadjuvanted oral doses (oral F1-V mice).

262 ids intravenously for 1 week then a tapering oral dose over 8 weeks.

263 vaginal dosing were 56-fold lower than after oral dosing (p<0.001).

264 >/=130-fold higher with vaginal compared to oral dosing (p<0.001).

265 and theoretically greater PrEP efficacy than oral dosing; randomized topical dosing PrEP trials to th

266 ucker diabetic fatty (ZDF) rats after single oral doses ranging from 0.1 to 1.0 mg/kg.

267 dipose, and in cynomolgus monkeys a 10 mg/kg oral dose reduced cortisol production by 85% following a

268 mouse average survival to 7.2 days with this oral dose regimen.

269 ange, 11.3 to 37.6), supporting a once-daily oral dosing regimen.

270 ministered MPTP with varying subcutaneous or oral dosing regimens of AEOL11207.

271 Oral dosing renders blood stage parasitaemia undetectabl

272 mately 100- and 40-fold lower than after TFV oral dosing, respectively).

273 ersion to an acetate prodrug 25b, which upon oral dosing resulted in an improved pharmacokinetic prof

274 a of the control group treated with the same oral dose rose to higher levels for 6-7 hours but then d

275 At only 3 x 10 mg/kg oral dosing, seven dimers prolong the lifetime of malari

276 harmacokinetics (DMPK) properties and, after oral dosing, showed pharmacodynamic knockdown of phospho

277 Adding a glucose tracer to the oral dose significantly enhances the assessment of insul

278 Daily oral dosing studies showed that mice tolerate doses of a

279 n uninflamed prostate following a single 3-g oral dose, such that it may be a potential option for pr

280 e against both stages in vivo, with a single oral dose sufficient to clear liver stage infection.

281 al blood mononuclear cells (PBMCs) following oral dosing, TFV-DP levels in vaginal lymphocytes decrea

282 On all days post-oral dose, the majority of isolates (64% to 98%) were th

283 After a single oral dose, the mean +/- SD maximal concentration of thia

284 In order to obtain a more stable form for oral dosing, the sulfhydryl group in conjugate 1 was con

285 he plasma exposure levels achieved following oral dosing, the time course of target inhibition in viv

286 After oral dosing, though, only 32 increased nitrate and nitri

287 w compounds administered at single 100 mg/kg oral doses to F. hepatica infected rats, 8 had statistic

288 exposure and long brain half-life following oral dosing to mice.

289 the importance of carefully considering the oral dose used in animal experiments and provides useful

290 Compared to oral dosing, vaginal dosing achieved much lower serum co

291 The half-life of plasma glucosamine after oral dosing was approximately 150 min, with no significa

292 Plasma glucosamine pharmacokinetics after oral dosing were determined in each subject using a high

293 sly on day 1 and were permitted to switch to oral dosing when clinically indicated.

294 and pharmacokinetic parameters suitable for oral dosing, which led to the discovery of (2R)-1-[4-(4-

295 n = 6) at various intervals up to 24 h after oral dosing with 500 mg of flucloxacillin.

296 icipants were assigned to receive 3 weeks of oral dosing with placebo or fluoxetine, 40 mg per day.

297 (HFD) to mice for 10 weeks, followed by five oral dosing with purified AHC or ovalbumin on alternate

298 Moreover, oral dosing with the Mnk inhibitor significantly suppres

299 Oral dosing with Wy14643 similarly induced Hilpda mRNA l

300 SK2801 had reasonable in vivo exposure after oral dosing, with modest clearance and reasonable plasma